Global HIV Drugs Market to Reach US$ 43.9 Billion by 2032, Impelled by Rising Prevalence of AIDS

July 14, 2022 | Healthcare

According to the latest report by IMARC Group, titled "HIV Drugs Market Report by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors-CCR5 Co-Receptor Antagonist, Fusion Inhibitors and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2024-2032," the global HIV drugs market reached a value of US$ 31.7 Billion in 2023. Human immunodeficiency virus (HIV) is a life-threatening virus that weakens the immune system by destroying the cells that aid the human body to fight against infections. It is generally spread through unprotected sexual contact or blood transmission via injection drugs. Even though there is no effective treatment available for HIV currently, it can be controlled through prescribed medications. Apart from this, the widespread awareness regarding antiretroviral therapy (ART), which is a combination of various medicines that help in reducing the rate of virus growth in the body and monitoring white blood cells to determine the effect of the virus on the immune system, is contributing to the market growth.

Global HIV Drugs Market Trends:

The global market is primarily driven by the increasing prevalence of acquired immunodeficiency syndrome (AIDS) among the masses. Along with this, the rising awareness among individuals regarding the treatments available for AIDS has propelled the product demand. Moreover, the rising initiatives undertaken by the government and non-government organizations (NGOs) for promoting awareness programs across the globe are creating a positive market outlook. Additionally, the increasing spending by public and private agencies on extensive research and development (R&D) activities, along with the rising clinical trials and product launches, are providing a boost to the market. In line with this, continuous technological advancements in drug manufacturing processes are impacting the market further. Furthermore, the proliferation of online pharmacies and the advent of home delivery models are offering lucrative growth opportunities for major market players. Other factors, including rapid urbanization, continuous improvements in the healthcare infrastructure, and the increasing number of research laboratories and diagnostic centers, are also positively influencing the market. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 43.9 Billion by 2032, exhibiting a CAGR of 3.6% during 2024-2032.

Market Summary: 

  • Based on the drug class, the market has been classified into nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist, and fusion inhibitors and others.
  • On the basis of the distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, online pharmacies and others. Presently, hospital pharmacies account for the largest market share.
  • Based on the region, the market has been divided into North America, Europe, Asia Pacific, the Middle East and Africa and Latin America. Among these, North America holds the leading position in the market.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of these players include Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Drug Class, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global HIV Drugs Market to Reach US$ 43.9 Billion by 2032, Impelled by Rising Prevalence of AIDS
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More